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. The WHO recommends that all people with HIV infection receive antiretroviral therapy (ART) ( Table 1) . ART has trans formed HIV infection into a chronic disease. As a con sequence, by the year 2030, a modelling study suggests that 73% of people with HIV infection will be aged ≥50 years and 78% of individuals living with HIV infection will have cardiovascular disease (CVD) 2 . As shown in Fig. 1 , individuals infected with HIV have been shown to be at an increased risk of CVD, includ ing sudden cardiac death 3 , acute myocardial infarction (MI) 4 , stroke 5 , peripheral artery disease and heart fail ure with either reduced or preserved ejection fraction 6 . This Review focuses on coronary heart disease in the setting of HIV infection.
Although ART controls the HIV infection, the dis ease is not cured; individuals must continue taking ART indefinitely, and, in this setting, chronic inflammation and immune activation persist, leading to downstream consequences including the development of athero sclerotic CVD (ASCVD) 7 . The population living with HIV is ageing, and, although traditional CVD risk factors are crucial contributors to CVD, HIV specific factors, including ART, chronic inflammation and immune acti vation, have a role in HIV associated CVD, including atherosclerosis. The atherosclerosis associated with HIV infection differs in important ways from athero sclerosis in the non HIV setting in terms of both aetio logical factors and clinical presentation. The low grade inflammation associated with HIV infection accele rates atherogenesis through a variety of mechanisms. For example, atherosclerotic plaques in patients with HIV infection are more likely to be non calcified and more prone to rupture than atherosclerotic plaques in patients without HIV infection 8, 9 . Around one half of MI events among patients with HIV infection are related to an imbalance in cardiac oxygen demand and supply rather than to atherothrombotic disease 10 . Finally, indi viduals infected with HIV who develop acute coronary syndrome (ACS) are, on average, a decade younger than uninfected patients with ACS and are more likely to be men who smoke and have low levels of HDL cholesterol (HDL C) 11 . In this Review, we address the epidemiology and clin ical features of CVD in people living with HIV infec tion and discuss the mechanisms of HIV associated ASCVD and the management of CVD risk factors in people with HIV infection. Although much of this infor mation is similar to that in people with CVD without HIV infection, important differences exist, particularly on the potential future therapies for CVD in people living with HIV.
HIV infection and coronary heart disease: mechanisms and management
Priscilla Y. Hsue * and David D. Waters
Abstract | Antiretroviral therapy has largely transformed HIV infection into a chronic disease condition. As such, physicians and other providers caring for individuals living with HIV infection need to be aware of the potential cardiovascular complications of HIV infection and the nuances of how HIV infection increases the risk of cardiovascular diseases, including acute myocardial infarction, stroke, peripheral artery disease, heart failure and sudden cardiac death, as well as how to select available therapies to reduce this risk. In this Review , we discuss the epidemiology and clinical features of cardiovascular disease, with a focus on coronary heart disease, in the setting of HIV infection, which includes a substantially increased risk of myocardial infarction even when the HIV infection is well controlled. We also discuss the mechanisms underlying HIV-associated atherosclerotic cardiovascular disease, such as the high rates of traditional cardiovascular risk factors in patients with HIV infection and HIV-related factors, including the use of antiretroviral therapy and chronic inflammation in the setting of effectively treated HIV infection. Finally , we highlight available therapeutic strategies, as well as approaches under investigation, to reduce the risk of cardiovascular disease and lower inflammation in patients with HIV infection.
Epidemiology of CVD in HIV infection
Before the advent of ART in the late 1990s, HIV infection almost always progressed to AIDS, with frequent oppor tunistic infections leading to death. Cardiomyopathy with systolic dysfunction was common in patients with AIDS and was associated with high short term mortal ity (Table 2 ). For example, in one small study from the pre ART era, median survival was 101 days in patients with AIDS with dilated cardiomyopathy compared with 472 days in patients with AIDS with normal ven tricular function 12 . Cardiomyopathy was attributed to direct HIV infection of the myocardium with or with out myocarditis, co infection with other viruses such as coxsackievirus B3 and Cytomegalovirus (CMV), opportunistic infections and nutritional disorders 13 . Pericardial effusions were also common and presaged a high shortterm mortality 14 . The incidence of HIV associated cardiomyopathy has decreased from the pre ART era, from 25.6 to 3.9 cases per 1,000 person years 15 . The phenotype of cardio myopathy has also changed markedly, from symptomatic systolic dysfunction with left ventricular dilatation in the pre ART era to asymptomatic systolic or diastolic dys function detected by echocardiography in ART treated patients with HIV infection. Whereas older ARTs, such as nucleoside reverse transcriptase inhibitors (NRTIs), were implicated in mitochondrial toxicity leading to dilated cardiomyopathy 16 , more recent studies have sug gested that protease inhibitor use is related to increased cardiovascular mortality and 30day re admission for heart failure 17 . A 2018 systematic review of 80 longitudinal studies of CVD in HIV cohorts, which included 793,635 indi viduals living with HIV, concluded that the risk of MI and stroke in patients with HIV infection was increased by 2.16 (95% CI 1.68-2.77) compared with unin fected individuals 18 . The magnitude of this increased risk is similar to that associated with major CVD risk factors, such as diabetes mellitus and hypertension 19 . Given that the prevalence of HIV infection is much lower than the prevalence of these traditional CVD risk factors, the overall influence of HIV infection on the risk of CVD would, at first glance, seem to be low; how ever, the global burden of HIV associated MI and stroke has tripled over the past two decades and now accounts for 2.6 disabilityadjusted life years on an annual basis 18 . The burden of traditional CVD risk factors is high in people with HIV infection. A study published in 2015 on the large VACS VC cohort showed that <2% of patients with HIV had optimal levels of traditional CVD risk factors 20 . However, the increased risk of MI in people with HIV infection persists after adjustment for these risk factors; in the same cohort, the increased risk of MI was approximately 50% after adjusting for Framingham risk factors, comorbidities and substance abuse 4 . The risk of MI was higher in those with higher HIV1 RNA levels in blood (≥500 copies per ml) and lower CD4 + T cell counts (<200 cells per µl), but the risk was still elevated in those with low HIV1 RNA levels and high CD4 + T cell counts 4 . Although most of the study participants were men, the risk of MI was also significantly increased in women with HIV infection 21 .
As with MI, the risk of stroke is also increased in people with HIV infection 18 . Globally, the risk of stroke in patients with HIV infection is approximately double that in individuals without HIV infection 18 , but, in one study from the USA, the HR was 1.40 (95% CI 1.17-1.69), decreasing to 1.21 (95% CI 1.01-1.46) after adjustment for demographic and stroke risk factors 5 . A much higher risk of stroke has been reported in African patients with HIV, in whom initiation of ART is usually delayed after infection, with the highest risk of stroke being during the first 6 months after starting ART 22 . Risk factors for stroke in African patients with HIV infection compared with uninfected patients with stroke included younger age, large artery disease and a low CD4 + T cell count after initiation of ART 23 .
The relationship between use of ART and the risk of MI is not straightforward. Case reports of MI in individ uals with HIV infection began to appear soon after the introduction of ART 24 (Table 2) . Early protease inhibi tors were associated with the incidence of MI in a 2007 report, in which each cumulative year of protease inhibi tor use was associated with a 10% increase in the risk of MI, even after adjusting for the changes in blood lipid levels caused by the protease inhibitor therapy 25 . Some of the newer protease inhibitors are likely to be safer. More recent reports indicate that among two widely used, recent generation protease inhibitors, atazanavir was not associated with an increased risk of CVD compared with darunavir 26, 27 . Abacavir, a widely prescribed NRTI, was reported in several observational cohorts to be associated with an increased risk of MI [28] [29] [30] [31] , possibly because this drug increases vascular inflammation and platelet reactivity 32 . However, other studies, including an FDA meta analysis 33 , do not show an increased risk of MI with abacavir. Nevertheless, US guidelines recom mend that abacavir be avoided or used with caution in individuals at high risk of CVD 34 . The START trial 35 demonstrated unequivocally that starting ART in adults with HIV infection and a CD4 + T cell count of >500 cells per μl reduced mortality and serious AIDS related and non AIDSrelated events
Key points
• As improvements to antiretroviral therapies have led to better control of HIv infection (although not cured it), individuals with HIv infection are now ageing, and cardiovascular disease is an important health concern in this patient population.
• Traditional risk factors including dyslipidaemia, hypertension, cigarette smoking, diabetes mellitus and metabolic syndrome are common among people with HIv infection and increase the risk of cardiovascular disease.
• In addition to traditional risk factors, characteristics related to HIv infection, including low CD4 + T cell count, nadir CD4 + T cell count and viral detectability, and some antiretroviral therapies are independently associated with increased risk of cardiovascular disease.
• In the setting of treated suppressed HIv replication, chronic inflammation and immune activation persist and are strongly predictive of mortality and cardiovascular events.
• Potential strategies to reduce the risk of cardiovascular disease in patients with HIv infection include targeting traditional risk factors, initiation of antiretroviral therapy to reduce inflammation and other approaches to lower inflammation, including gut-related interventions, statin therapy and immune modulators.
CD4 + T cell counts
T cell subset that has a role in the immune system response against pathogens, infections and illnesses. a normal CD4 + T cell count is 500-1,500 cells per µl of plasma. CD4 + T cells are the main target cell of HiV, and the CD4 + T cell count is used to monitor the status of the HiV infection and the efficacy of the antiretroviral therapy.
www.nature.com/nrcardio compared with starting ART therapy after the CD4 + T cell count had declined to 350 cells per μl. However, the incidence of cardiovascular events was low in this study, and, although a nonsignificant trend towards a reduction in the risk of cardiovascular events with early initiation of the treatment was observed, no definitive benefit was demonstrated. In substudies of the START trial, early initiation of ART did not improve arterial elasticity 36 and led to increased total and LDL cholesterol (LDLC) levels in plasma but also to increased HDLC levels and lower use of antihypertensive medications compared with delayed ART initiation 37 . Therefore, the effect of early initiation of ART on the risk of CVD remains unknown.
Earlier initiation of ART and the use of safer forms of ART from a CVD risk perspective might have resulted in a decrease in the risk of MI over the past decade, but additional studies with longer term follow up will be needed to evaluate definitively the effect of early initia tion of ART on cardiovascular events. Some studies have reported a declining relative risk of MI in the setting of HIV infection 38 , which might be related to the use of newer protease inhibitors 27 , better control of HIV infec tion 39 or modification of traditional CVD risk factors over time 40 , including smoking 41 . Thus far, no studies have reported on the effect of integrase inhibitors on cardiovascular events in HIV infection.
Clinical features of HIV-associated CVD Early reports of coronary heart disease among individu als with HIV infection were remarkably consistent in the described clinical characteristics 11, 33, [42] [43] [44] [45] [46] [47] . Patients with HIV infection and coronary heart disease in these stud ies were >90% men and had a mean age of 42-50 years, about a decade younger than patients with ACS with out HIV infection in the reports with control groups 11 .
More than half were current smokers 11, 33, [42] [43] [44] 46, 47 , and, in studies including blood lipid measurements, plasma HDL C levels were lower in patients with coronary heart disease and HIV infection than in uninfected patients with coronary heart disease 11, 43 . As would be expected in the population with HIV infection, single vessel disease NATuRe RevIews | CARDIOlOGY was common 11, 43, 46, 47 , and, in those with ACS, risk scores were lower than in individuals with ACS without HIV infection 11 . Therefore, as expected, in hospital mortality in patients with ACS and HIV infection was not high for that era: 4.8% (9 of 189 patients) in the studies in which this outcome was reported 11, 42, 43, 46, 47 . Coronary angioplasty in these early studies was as effective in patients with HIV infection as in patients without HIV infection; however, restenosis was more common in the setting of HIV infection 11, 43 . The wide spread use of coronary stents has reduced the incidence of restenosis, and drug eluting stents have been shown to reduce cardiovascular events in patients with or with out HIV infection 48 . Nevertheless, in a small study in which follow up coronary angiography was performed routinely in individuals with HIV infection undergoing coronary stenting, the incidence of restenosis with drug eluting stents was 19% 49 . Total CD8 + T cell count, but not CD4 + T cell count, was associated with restenosis, as was plasma C reactive protein (CRP) level at follow up (but not baseline) 49 . These results suggest that persistent inflammation in patients with HIV infection might be causally related to restenosis.
In a contemporary cohort of 226 patients with HIV infection who were followed up for 3 years after hospi talization for ACS, the risk of recurrent ACS was not increased compared with individuals without HIV infection (HR 1.08, 95% CI 0.76-1.54) 50 . HIV infection was significantly associated with all cause mortality, but this association was not present among individ uals with CD4 + T cell counts ≥500 cells per μl. These intermediate term results are encouraging; however, longer term follow up studies of patients with HIV infection and coronary heart disease are lacking. Imaging studies have provided insight into the fea tures and pathophysiology of HIV associated coronary heart disease. Overall stenosis was less severe among men with ACS and HIV infection than in matched, uninfected individuals with ACS, although the num bers of diseased coronary vessels and lesions were sim ilar in both groups 51 . In another study, plaque burden assessed as lesion severity in intracoronary ultrasono graphy findings was also lower in patients with ACS and HIV infection than in patients with ACS without HIV infection 52 . Furthermore, hyperechoic, non calcified coronary plaques were much more common in patients with HIV (100% versus 35%; P < 0.05).
A higher prevalence of non calcified coronary lesions among patients with HIV than in individuals without HIV infection was also reported in a meta analysis of individuals without coronary symptoms who were eval uated with coronary CT 9 . In nine studies with 1,229 patients infected with HIV and 1,029 controls without HIV infection, the rates of non calcified coronary plaques were higher in the HIV group (58% versus 17%; OR 3.26, 95% CI 1. 30-8.18 ). Some evidence suggests that these non calcified plaques are particularly amenable to LDL C lowering with statin therapy. In a small clinical trial in which patients with HIV infection were ran domly assigned to receive atorvastatin or placebo and followed up for 1 year, atorvastatin significantly reduced non calcified coronary plaque volume compared with
Pre-ART
No HIV-specific therapy In the pre-ART era, dilated cardiomyopathy and pericardial effusions were the most commonly reported cardiovascular issues in patients infected with HIV 14, 176 . After the introduction of protease inhibitors (PIs) in the late 1990s, atherosclerotic complications including myocardial infarction were described 177, 178 . More recently , reports of heart failure and rhythm abnormalities are now emerging in the setting of HIV infection 3, 6 . In the future, among individuals with access to ART, HIV infection will be a chronic disease state with increased risk of coronary artery disease 19 . CCR5, CC-chemokine receptor 5; NNRTI, non-nucleoside reverse-transcriptase inhibitor ; NRTI, nucleoside reverse-transcriptase inhibitor.
www.nature.com/nrcardio placebo 53 . Why individuals infected with HIV have a higher prevalence of non calcified coronary plaques has yet to be established but does not seem to be related to ART 54 and might be due to chronic inflammation and immune activation in treated HIV infection 55, 56 .
Mechanisms of HIV-related atherogenesis
The pathogenesis of atherosclerosis in the setting of HIV infection is complex and poorly understood. Underlying mechanisms for HIV associated ASCVD include the effects of the HIV proteins on immune and vascular cells, the immunodeficiency caused by the HIV infec tion, co infection with CMV, microbial translocation from the gut, chronic inflammation and immune cell activation. These factors and their interrelationships are depicted in Fig. 2 and are summarized below.
HIV proteins. In individuals receiving ART, the HIV infection, although controlled, is not cured and there fore persists even when the virus is undetectable 57 , with low level transcription of HIV genes 58 . HIV encoded proteins, specifically transactivator of transcription (Tat) and negative factor (Nef), induce inflammation and endothelial dysfunction 59 . In addition, the HIV envelope protein gp120 has been shown to stimulate endothelin 1 production 60 . Therefore, by releasing low levels of certain damaging proteins, the HIV virus itself stimulates atherogenesis. ART, antiretroviral therapy ; CVD, cardiovascular disease; IMT, intima-media thickness; MI, myocardial infarction; NNRTI, non-nucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor ; VA , Veterans Affairs.
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Immunodeficiency. CD4 + T cell depletion is the hallmark of HIV infection, and nadir CD4
+ T cell count is a rough marker of the severity of immunodeficiency. Nadir CD4 + T cell count was first linked to features of atherosclero sis, such as increased carotid intima-media thickness 61 and increased arterial stiffness 62 . Soon thereafter, lower nadir CD4 + T cell counts were shown to be associated with incident MI in two cohort studies 63, 64 . In another report in which cardiovascular events were adjudicated more stringently, type 1 MI (the atherothrombotic type) occurred more commonly in people either with lower CD4 + T cell counts or with detectable HIV RNA 65 . The CD4:CD8 ratio, a marker of immunosenescence, has been predictive of cardiovascular events in some 66, 67 but not other 68 studies. Among individuals with HIV infection in New York City, USA, CVD mortality was highest among individuals with detectable viraemia (adjusted rate ratio (RR) 3.53, 95% CI 3.21-3.87), although even individuals with viral suppression had elevated CVD mortality (adjusted RR 1.53, 95% CI 1.41-1.66) com pared with the general population 69 . These findings indicate that markers of immune system damage and viral detectability are related to cardiovascular events in patients with HIV. Immune abnormalities persist in individuals with HIV infection even after successful treatment with ART. The mechanisms linking immune system damage in HIV infection to atherosclerosis have not been elucidated. Although non AIDSrelated events, such as MI and stroke, are less common with com plete viral suppression, these events still occur at rates considerably higher than in an uninfected population.
CMV co-infection. Co infection with CMV might con tribute to HIV associated atherosclerosis. Compared with individuals without HIV infection, patients infected with HIV consistently have a higher propor tion of CMV specific CD8 + T cells, with the highest levels seen in patients with HIV suppression who are Finally , strategies to lower inflammation, such as canakinumab, which has been reported to reduce cardiovascular events significantly in a non-HIV patient population, might also reduce the risk of HIV-associated ASCVD.
Nadir CD4 + T cell count
The lowest CD4 + T cell count an individual has had, which serves as a marker for immunodeficiency.
Immunosenescence
Changes to the immune system that can be associated with age.
Viraemia
Presence of viral particles in the blood.
www.nature.com/nrcardio receiving long term ART 70 . CMV specific responses seem to underlie immunosenescence or immunological ageing in HIV infection 71 . Co infection with CMV is strongly linked to HIV viral persistence and might also have a role in chronic immune activation and inflam mation by expansion of the HIV reservoir 72 . These CMV specific T cell responses also have been shown to correlate with markers of atherosclerosis, such as carotid intima-media thickness [73] [74] [75] and coronary artery calcifi cation 75 . High CMV antibody titres in patients with HIV infection, and titres to other viruses such as herpes sim plex virus and varicella zoster virus, are associated with higher levels of biomarkers that accelerate inflamma tion and atherosclerosis 74 . Analogously, CMV also has an important role in the coronary atherosclerosis that develops in heart transplantation recipients 76 .
Gut microbial translocation. Impairment of the gut barrier is an early feature of HIV infection, leading to microbial translocation, a process whereby microbial products leak through the intestinal barrier and cause immune activation 77 . Plasma levels of soluble CD14 (sCD14) and lipopolysaccharide are markers of micro bial translocation that independently predict HIV dis ease progression 78 and mortality 79 in individuals who are not receiving ART. Conflicting data exist as to whether these markers are predictive of adverse outcomes in ART treated individuals; however, gut damage and microbial translocation persist even when HIV infection is suppressed by ART 77 . Plasma levels of inflammatory markers, specifically IL6 and tumour necrosis factor, have been reported to be higher in individuals with higher levels of markers of microbial translocation 80 . Therefore, microbial translocation is another mechanism that might contribute to the atherogenesis associated with HIV infection. However, interventions targeting this mechanism, including sevelamer 81 , rifaximin 80 , probiotic administration 82 and mesalamine 83 , have not consistently lowered inflammatory markers or T cell activation. As these studies targeted a variety of patient populations (treated versus untreated HIV infection), evaluated different inflammatory markers and were gen erally short in duration, the definitive role of microbial translocation from the gut in HIV associated ASCVD remains unclear and requires additional investigation.
Chronic inflammation and immune cell activation.
latent HiV infection, co infection with other viruses and microbial translocation all influence atherogene sis by increasing inflammation. HIV infection is asso ciated with high levels in plasma of inflammation and coagulation markers, such as CRP, IL6 and d dimer, and these biomarkers strongly predict cardiovascular events and all cause mortality in individuals with HIV infection [84] [85] [86] . Arterial and lymph node inflammation as assessed by FDG PET and CT imaging are higher in patients with HIV infection than in individuals without HIV infection, and this increased inflammation cor relates with higher circulating levels of CRP, IL6 and activated monocytes 87, 88 . Inflammation offers a potential therapeutic target for the reduction of cardiovascular events in individuals with or without HIV infection; some postulated thera pies to lower inflammation in HIV infection are depicted in Fig. 2 . In patients with atherosclerosis without HIV infection, the beneficial effect of statin therapy is thought to be due not only to a reduction in plasma LDL C levels but also to a reduction in inflammation 89 . In the presence of HIV infection, the anti inflammatory effects of statins on markers of inflammation seem to be attenuated 90, 91 . Changing protease inhibitorbased regimens to integrase inhibitors does not consistently reduce inflammatory parameters 92 , and intensification of ART does not have a major salutary effect on inflammatory markers 93, 94 . Short studies of aspirin therapy also had no effect on inflam matory markers in HIV infection 95 . Taken together, these findings suggest that strategies in addition to ART and targeting of traditional CVD risk factors are needed to reduce inflammation with the aim of lowering the risk of ASCVD in the setting of HIV infection.
Although T cell activation is a strong predictor of HIV disease progression 96 , inflammatory and coagula tion biomarkers, including IL6, soluble tumour necrosis factor receptor type I (sTNFRI), tumour necrosis factor receptor type II (TNFRII), kynurenine:tryptophan ratio and d dimer, but not T cell activation, were predictive of non AIDS events including CVD 97 . Some studies have implicated T cell activation in HIV infection with other indices of atherosclerosis, including carotid artery intima-media thickness 98 and arterial stiffness 99 . The effect of T cell activation in HIV associated vascular disease seems to be at the microvascular level, which serves as the stimulus for flow mediated vasodilata tion (a marker of macrovascular disease) 100 . Therefore, T cell activation in HIV infection might worsen micro vascular disease, leading to endothelial dysfunction and subsequent cardiovascular events.
Canakinumab, a monoclonal antibody targeting IL1β, was evaluated in a randomized, placebocontrolled trial involving 10,061 patients with previous MI and a high sensitivity CRP (hsCRP) level of ≥2 mg/l (reF. 101 ).
The three doses of canakinumab that were tested all reduced hsCRP levels, ranging from 26% reduction with the 50 mg dose to 41% with the 300 mg dose, but did not affect LDL C levels. At the intermediate and higher doses, canakinumab reduced the primary composite end point of CVD related death, MI and stroke. Patients who had a hsCRP reduction to <2 mg/l had significant reduc tions in cardiovascular events, CVD related mortality and all cause mortality, whereas no significant reduc tion in these outcomes was observed in patients who did not achieve the hsCRP reduction to this level 102 . Similar findings were reported for individuals who achieved on treatment IL6 levels below the study median value of 1.65 ng/l -namely, a 32% reduction in major adverse cardiovascular events, a 52% reduction in CVD related mortality and a 48% reduction in all cause mortality 103 . Canakinumab therapy was associated with a higher incidence of fatal infection than placebo 101 . Would canakinumab reduce cardiovascular events in individuals infected with HIV? In a small study in patients with HIV infection, our group has shown that canakinumab therapy significantly reduced plasma IL6 and hsCRP levels, with no effect on CD4, CD8 or RNA NATuRe RevIews | CARDIOlOGY viral levels 104 . Inflammation in the bone marrow and arterial inflammation were reduced after a single dose of canakinumab. By contrast, in another study published in 2018, low dose methotrexate significantly lowered the CD8 + T cell count but had no effect on inflammatory markers or endothelial function 105 . However, low dose methotrexate did favourably affect specialized ultra sonography indices in the brachial artery 106 . These preliminary studies with inflammatory biomarkers as surrogate end points will hopefully lead to clinical trials on anti inflammatory treatments with cardiovascular events as end points in the population living with HIV.
As previously noted, markers of inflammation and coagulation predict cardiovascular events in individu als with HIV infection [84] [85] [86] . A summary of markers stud ied in different cohorts of patients with HIV infection and the association with clinical outcomes is shown in Table 3 . The strong relationship between inflammatory and coagulation markers is striking and apparent even in the setting of diverse HIV infected populations includ ing men, women and older and younger individuals. In combined data from three large cohorts of patients with HIV infection, IL6 and d dimer levels in plasma were independently associated with the risk of seri ous non AIDS events or death, with an estimated 37% reduction in non AIDS events or death resulting from a 25% decrease in IL6 or d dimer levels 107 . Aside from prediction of clinical events, plasma levels of soluble CD163 (sCD163), a marker of macrophage activity, was associated with higher levels of arterial inflammation in HIV infection 87 .
In the general population, the immune system has been implicated in atherosclerosis as well as in con duction system disorders, myocarditis and heart fail ure with preserved ejection fraction 108 . In particular, the role of haematopoietic stem cells, inflammation and macrophages has been associated with these con ditions; therefore, it is plausible that immune system abnormalities that are present in HIV infection underlie HIV associated CVDs. HIV infects CD4 + T cells, most of which reside in secondary lymphoid tissues, such as the lymph nodes 109 . Myeloid cells, which include mono cytes, dendritic cells and macrophages, have a crucial role in HIV disease pathogenesis 110, 111 . Macrophage infiltration has been observed in the hearts of monkeys infected with simian immunodeficiency virus (SIV), and macrophage infiltration correlated with fibrosis and car diac pathology 112 . Anti inflammatory therapy with natalizumab (a monoclonal antibody against the cell adhesion molecule α4 integrin) reduced the number of macrophages in cardiac tissue as well as cardiac pathol ogy in this animal model 113 . Monocyte and macrophage markers, including sCD163 and sCD14 levels in plasma and CD14 + CD16 + cell counts, have been linked to subclinical atherosclerosis in HIV infection in a variety of studies 113 . A 2018 study showed that biomarkers in HIV infection can be grouped into clusters, with each clus ter related to a cardiac phenotype 114 . For example, the inflammatory phenotype is characterized by higher levels of CRP, IL6 and d dimer, whereas the cardiac phenotype comprised a clustering of higher levels of protein ST2 (also known as IL1 receptor like 1), Nterminal pro Btype natriuretic peptide and growth/ differentiation factor 15. Diastolic dysfunction was common in the inflammatory group of biomarkers, and pulmonary hypertension was more common in the cardiac group of markers. Both phenotypes were associated with a threefold increase in mortality over a 6.9year follow up after adjustment for other prognostic variables. Biomarker clusters in patients with HIV might be helpful for selecting patients for appropriate therapy to reduce cardiovascular events.
ART-related mechanisms. The most obvious mecha nism by which ART increases the risk of CVD is through worsening of blood lipid levels. The increase in LDLC levels with protease inhibitors seems to result from ART, antiretroviral therapy ; CRP, C-reactive protein; CVD, cardiovascular disease; hsCRP, high-sensitivity C-reactive protein; KT, kynurenine:tryptophan; sCD14; soluble CD14; sTNFRI, soluble tumour necrosis factor receptor type I; sTNFRII, soluble tumour necrosis factor receptor type II.
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increased cholesterol absorption rather than increased synthesis 115 . Whereas some ARTs increase LDL C levels, other ARTs, particularly older protease inhibitors, induce hypertriglyceridaemia, with ritonavir being the worst culprit 116 . Interestingly, in the large D:A:D study 117 , even after adjustment for blood lipid levels, cumulative exposure to the NRTIs abacavir or didanosine or to the protease inhibitors lopinavir-ritonavir or indinavir was associated with an increased risk of MI. Newer protease inhibitors, as well as the integrase inhibitor raltegravir and the virus entry inhibitor maraviroc, have favourable effects on lipid levels, particularly compared with older types of ARTs 118 . ART might also increase the risk of ASCVD through other mechanisms. Insulin resistance, lipodystrophy and other patterns of fat distribution can contribute to atherogenesis. The NRTI abacavir has been linked to an increased risk of MI in some [28] [29] [30] [31] but not all studies 33 . This increase in risk has been attributed to increased platelet reactivity 32 and to endothelial dysfunction 119 . In the D:A:D study 26 , a difference in the risk of MI was noted between the widely used protease inhibitors, atazanavir and darunavir, with atazanavir being associ ated with a lower risk of MI than darunavir. This reduced risk of MI has been suggested to reflect a protective effect of atazanavir given the bilirubin raising activity of the drug 120 . Overall, we emphasize that current ART regi mens are associated with a much lower risk of CVD than older ART regimens.
Understanding the role of inflammation and inflam matory biomarkers in the general population with coronary heart disease has taken several decades to establish 121, 122 , including ascertaining which markers have prognostic importance as opposed to being on the causal pathway. Although research on inflammatory bio markers of the risk of CVD in HIV infection has been performed, much additional work is needed to iden tify the best biomarker in the setting of HIV infection along with the effect of HIV related factors (including immune dysfunction) and traditional CVD risk factors. Identifying how ART, treatments for CVD and potential anti inflammatory strategies change these inflammatory pathways and biomarkers will also be critical to advance the field. Of note, risk calculators used in the general population are inaccurate in patients infected with HIV and systematically underestimate risk 123 . Using non biased methods, such as proteomics, which have been used in the general population, might be helpful to develop HIV specific risk scores 124 .
Management of CVD risk in HIV infection
Dyslipidaemia. The onset of HIV infection is asso ciated with a decline in total cholesterol, LDL C and HDL C levels 125 . In a study comparing patients with HIV infection with matched uninfected controls, the group with HIV infection had lower HDL C and LDL C levels and higher triglyceride, CRP and IL6 levels 126 . Because starting ART is now recommended at the time of initial HIV diagnosis, the lipid pattern of untreated HIV infection is seen only among individu als who live in resource limited settings and, therefore, do not have access to ART. Of note, in a meta analysis of 80 studies, the greatest risk of CVD in HIV infec tion was found to be in sub Saharan Africa and the Asia Pacific regions 18 . The effect of ART on blood lipid levels varies across the classes of ART drugs and between drugs within the same class, as broadly summarized in Table 4 (of note, this summary is not meant to be comprehensive). The effects of individual drugs are difficult to ascertain because HIV treatment typically requires three or four drugs. Generally, protease inhibitors, NRTIs and non NRTIs (NNRTIs) all increase triglyceride levels and can increase LDL C levels. LDL C and triglyceride levels increase more with dual than with single protease inhibitor therapy. Important differences have been described between protease inhibitors; in a report from the D:A:D study 116 , ritonavir and ritonavir containing regimens increased triglyceride and LDL C levels more, saquinavir caused less abnormally low HDL C levels and nelfinavir was associated with fewer patients presenting with a high total cholesterol:HDL C ratio compared with other pro tease inhibitors. In another study, LDL C level increased by a mean of 2.0 mmol/l with initiation of ritonavir, 0.8 mmol/l with indinavir and 1.2 mmol/l with nelfina vir 127 . Ritonavir, but not the other two protease inhibitors, was associated with very elevated plasma triglyceride levels. Ritonavir can sometimes cause extreme hypertri glyceridaemia, with levels >10 mmol/l, and result in pan creatitis. Lower doses of ritonavir than those used in the study are now usually used, but hypertriglyceridaemia is also seen with combinations of ritonavir-saquinavir and ritonavir-lopinavir. Compared with these older protease inhibitors, use of atazanavir and darunavir is associated with more favourable lipid profiles 128 . NNRTIs also increase LDL C levels but do not decrease HDL C levels 13 . Among NNRTIs, efavirenz was associated with slightly more patients developing hypercholesterolaemia and hypertriglyceridaemia than nevirapine 116 . Efavirenz has been associated with greater increases in total cholesterol and LDL C but not total cholesterol:HDL C ratio compared with the atazanavirritonavir combination 129 . Compared with the NNRTI rilpivirine, efavirenz is associated with higher total cho lesterol, HDL C, LDL C and triglyceride levels 130 . The newer formulation of the NRTI tenofovir (tenofovir alafenamide) is associated with higher levels of both LDLC and HDLC, but similar total cholesterol:HDLC ratio, compared with the older formulation (tenofovir disoproxil fumarate), which has a lipid lowering effect 131 .
Newer ARTs, such as the integrase inhibitors, the CC chemokine receptor 5 (CCR5)co receptor antago nist maraviroc and second generation protease inhib itors, such as atazanavir, favourably affect lipid levels, especially compared with older ARTs, and are associ ated with improvements in surrogate markers of athero sclerosis, such as flow mediated vasodilatation and carotid intima-media thickness 132 . The integrase inhibi tors dolutegravir and raltegravir seem to affect blood lipids in a similar way 133 . Across various studies, the prevalence of hyper lipidaemia among people living with HIV ranges from 28% to 80%, with hypertriglyceridaemia being the most common abnormality 134 . Intrinsic differences in study populations and the evolution of ART over time are probable explanations for this broad range. Most of the studies described here were of fairly short duration and were usually done in North American or European popu lations. However, ART is now initiated most often in people living in sub Saharan Africa, where data defining the metabolic effects of treatment are scarce. In a 2018 meta analysis of 14 trials and including a total of 21,023 individuals from this region, ART was associated with an increased risk of hypertriglyceri daemia (RR 2.05, 95% CI 1.51-2.77); however, no con sistent associations were observed between ART and raised blood pressure, blood glucose levels, glycated haemoglobin (HbA 1c ) levels or other blood lipids 135 . In one study, hypertriglyceridaemia in patients with HIV infection was related to their higher intake of total fat, saturated fat and cholesterol compared with individ uals without HIV infection 136 . Saturated fat intake was strongly correlated with triglyceride levels, suggesting that dietary modification to decrease saturated fat intake might be a logical approach to control high triglyceride levels in patients with HIV infection.
Until recently, guidelines for cholesterol management have not specifically addressed individuals living with HIV. The 2016 ESC/European Atherosclerosis Society (EAS) guidelines devote a short section to individuals with HIV infection and recommend dietary changes and exercise, as well as switching, when feasible, to a more 'lipid friendly' ART 137 . The guidelines also state that statin therapy should be considered to achieve the target LDL C level of 2.8 mmol/l, the same target that is recommended for other patients at high risk of CVD. The US National Lipid Association recommended con sidering HIV infection as an independent risk factor for selecting drug therapy to lower LDL C levels 138 . The 2018 ACC/AHA guidelines state that HIV infection can be considered a CVD risk enhancer, which would favour starting moderate intensity or high intensity statin therapy 139 . Many clinical trials have documented that LDL C lowering, usually with statin therapy, reduces the risk of cardiovascular events across a broad spectrum of patients without HIV infection. Similar data are not yet available for people with HIV infection; however, the REPRIEVE trial 140 , launched in 2015, will address this issue. As previously noted, in a small, randomized trial in patients with HIV infection, atorvastatin signif icantly reduced non calcified coronary plaque volume compared with placebo during a follow up of 1 year 53 . Drug-drug interactions are important considera tions when initiating lipid lowering drugs in patients infected with HIV. A systematic review of 18 statin trials in patients with HIV infection receiving ART demon strated that statin therapy can be administered safely in this patient population 141 . Use of lovastatin and simvas tatin with protease inhibitors is contraindicated owing to the risk of rhabdomyolysis from high statin levels in blood 134 . Use of ritonavir with protease inhibitors seems to increase the area under the curve for atorvastatin as well; therefore, guidelines from the Infectious Diseases Society of America suggest starting at lower doses of atorvastatin in individuals receiving protease inhibitor based regimens 142 . Rosuvastatin levels in blood increase when used with atazanavir-ritonavir and lopinavirritonavir; therefore, the dose of rosuvastatin should be limited to 10 mg when used in combination with these drugs 143 . Pravastatin and fluvastatin are safer to use in combination with ART but do not lower LDL C levels as much as atorvastatin or rosuvastatin. Pravastatin and fluvastatin were widely used after the introduction of ART but are less popular now owing to the growing realization, reflected in contemporary guidelines, that greater degrees of LDL C lowering yield greater reduc tions in the risk of cardiovascular events 144 . Pitavastatin might be a good compromise for some people with HIV infection; this drug is metabolized via glucuronidation, thereby avoiding drug-drug interactions 145 , and, at higher doses, pitavastatin shows moderate LDL C low ering. In one randomized study in patients with HIV infection, pitavastatin (4 mg per day) reduced LDL C level by 31% and pravastatin (40 mg per day) reduced LDL C level by 21% from baseline levels, with similarly low rates of adverse effects for both statin treatments 146 . According to a 2018 study, as many as 50% of individuals with HIV infection were eligible for statin therapy on the basis of at least one US guideline, but not all the eligible patients were prescribed statins 147 . Even when individu als are receiving statin therapy, those with HIV infection might not achieve as much lipid lowering as individuals without HIV infection; namely, a meta analysis of stud ies in people living with HIV infection demonstrated that only a low percentage achieved the expected reduc tion in LDL C level after initiation of statin therapy 148 .
www.nature.com/nrcardio 150 . Ezetimibe can be used in addition to a maximally tolerated statin dose for indi viduals with HIV infection who are at a very high risk of CVD and do not achieve satisfactory LDL C lowering with statin therapy alone. Use of bile acid sequestrants is not appropriate in the setting of HIV infection because these agents increase plasma triglyceride levels and their effect on the absorption of ARTs is unknown 151 . Individuals with HIV infection often have a high pill burden, and an add on therapy might present additional challenges.
Switching ART to drugs that do not adversely affect blood lipids is worthwhile as long as viral suppression is maintained. Switching from older protease inhibitors to integrase inhibitors improves blood lipid levels, but at the cost of an increased rate of virological failure 152 and, therefore, is not recommended for individuals with a history of virological failure. In another study of patients with HIV infection and high risk of CVD, continuing on a ritonavir boosted protease inhibitor regimen or switching to dolutegravir (an integrase inhibitor) was associated with similar rates of virological failure after 48 weeks; however, total cholesterol, LDL C and trigly ceride levels all improved (P < 0.0001) in the dolutegravir group 153 . For those not already taking a statin, adding statin therapy is probably preferable to switching the type of ART; in one study, adding rosuvastatin (10 mg per day) was better tolerated and yielded better blood lipid results than switching 154 . The common problem of hypertriglyceridaemia in patients with HIV infection should first be addressed by reducing intake of carbohydrates, including alco hol. When plasma triglyceride levels exceed 10 mmol/l, pancreatitis is a serious risk and immediate treatment is required, but lower levels of hypertriglyceridaemia are not benign because they probably increase the risk of CVD. Fibrates are widely used to lower triglyceride levels in people without HIV infection but have a drug-drug interaction with statins and some types of ART. A change in ART to drugs that induce less hypertriglyceridaemia is often the best approach.
Diabetes and the metabolic syndrome. Whether HIV infection itself is associated with an increased risk of diabetes or whether the increased risk is related only to specific ART drugs has been controversial. Protease inhibitors and the thymidine analogue stavudine can cause insulin resistance 118 ; however, these drugs are now not often used owing to their toxicity. In a large cohort study from Denmark, the risk of diabetes among patients with HIV infection was nearly triple that of the general population in 1996-1999, but this excess was absent in 1999-2010 (reF. 155 ). Conversely, a cross sectional study from sub Saharan Africa published in 2018 reported a higher prevalence of diabetes and a HbA 1c level of ≥6% in people living with HIV infection compared with uninfected controls 156 . Lipodystrophy is a syndrome that results in central adiposity from fat accumulation in the dorsocervical region, increased or preserved visceral fat and periph eral fat loss 157 and can be divided into lipoatrophy and lipohypertrophy 158 . Excess visceral adiposity is associ ated with insulin resistance among individuals with or without HIV infection 159 . Lipodystrophy develops in 20-35% of patients taking older protease inhibitors or the NRTIs didanosine or stavudine 160, 161 ; however, newer protease inhibitors, such as atazanavir, do not seem to cause lipodystrophy 37, 160, 161 . Lipodystrophy is often associated with insulin resistance, impaired glu cose tolerance, hypertriglyceridaemia, low HDL C levels and hypertension.
Reported rates of metabolic syndrome in people with HIV infection range from 8.5% to 52%, with rates at the lower end of this range seen in multicentre studies in which patients had less exposure to ART and rates at the higher end found in Latin American countries 118 . Metabolic syndrome usually develops in the first 3 years after starting an ART regimen that includes lopinavirritonavir or stavudine. According to most studies, meta bolic syndrome is a predictor of cardiovascular events and death in people living with HIV infection, as in individuals without the infection 118 . Among the general population, development of chronic kidney disease is increased in the setting of metabolic syndrome 162 , and blood pressure is a component of metabolic syndrome using Adult Treatment Panel III (ATP III) criteria 163 . The prevalence of hypertension and chronic kidney disease does not seem to be higher than normal in people with HIV infection, with the exception of a higher inci dence of chronic kidney disease among patients exposed to some ART regimens 164 . Nevertheless, hypertension and prehypertension have been shown to be risk factors for cardiovascular events in people with HIV infection, just as in individuals without the infection 165 . Similarly, chronic kidney disease, defined as either albuminuria or a decreased glomerular filtration rate, is associated with an increased risk of cardiovascular events in patients with HIV infection 166 . Among 35,357 patients with HIV in the D:A:D cohort, lower glomerular filtration rate was strongly associated with a higher risk of CVD 167 .
Smoking. The prevalence of cigarette smoking among individuals with HIV infection is extremely high. In a large cohort study from Denmark, nearly half of people with HIV infection smoked compared with one fifth of people without HIV infection 168 . All cause mortality was much higher among smokers than nonsmokers with HIV infection. For example, an individual aged 35 years and living with HIV infection had a median life expec tancy of 62.6 years (95% CI 59.9-64.6 years) if a smoker and 78.4 years (95% CI 70.8-84.0 years) if a nonsmoker. More life years were lost owing to smoking than to HIV (12.3 versus 5.1). The population attributable risk of death due to smoking was 61.5% in individuals with HIV and 34.2% among people without the infection. These statistics emphasize the importance of stopping smoking for patients with HIV infection.
Virological failure
refers to the failure of the HiV treatment to supress the virus completely; the virus is detectable in the blood (>200 copies per ml). This failure can occur as a result of drug resistance, drug toxicity or noncompliance with antiretroviral therapy.
Smoking cessation programmes are reported to have the same modest success rates in people with HIV infec tion as has been reported in individuals without HIV infection. In a meta analysis of eight trials including 1,822 patients with HIV who were smokers, behavioural interventions increased abstinence rates by half (relative risk 1.51, 95% CI 1.17-1.95) 169 , and a meta analysis of smoking cessation interventions demonstrated that long term outcomes were similar among individuals with or without HIV infection 170 . In one study, physi cians trained to provide smoking cessation counselling and treatment for individuals living with HIV infection succeeded in significantly increasing smoking cessation rates and decreasing relapse rates 171 . Potential drugdrug interactions between ART and drugs for smoking cessation have not been well studied. Studies of varen icline, bupropion and nicotine replacement therapy in people with HIV infection have generally been small, short and uncontrolled but have shown similar safety and success rates to reports in individuals without HIV infection 172, 173 . The effect of smoking cessation on the rates of sub sequent cardiovascular events was reported for a large cohort in the D:A:D study 174 . At baseline, 11,951 par ticipants (44%) were currently smoking and during the follow up period, 69% of them stopped smoking at least once. The incidence RR for MI compared with never smokers decreased from 3.73 (95% CI 2.46-5.64) within the first year of smoking cessation to 3.00 (95% CI 1.84-4.88) within 1-2 years, to 2.62 (95% CI 1.42-4.83) at 2-3 years and to 2.07 (95% CI 1.19-3.63) after >3 years. Similar trends were seen for total coronary events and total cardiovascular events. Although cardio vascular event rates were still approximately double the rate in never smokers after 3 years, the rates were much lower than the rates in individuals who continued smoking, making smoking cessation a very desirable therapeutic goal.
Conclusions
In summary, atherosclerosis in the setting of HIV infec tion continues to be an important health concern that has implications on mortality, particularly in the future as this patient population continues to age. In the 20 years since the initial descriptions of MI were reported in patients with HIV infection 175 , ART has transformed HIV infection into a chronic disease condition, and pro gress has been made in determining the contribution of ART, chronic inflammation and immune activation as well as traditional CVD risk factors to this disease pro cess. However, much work remains to elucidate further the underlying mechanisms for HIV associated ASCVD as well as therapeutic strategies to lower the risk of CVD and treat CVD in patients with HIV infection, which will include implementation studies to improve outcomes and CVD management for people living with HIV infection.
